A phase II study of Endostatin in combination with paclitaxel, carboplatin, and radiotherapy in patients with unresectable locally advanced non-small cell lung cancer

BMC Cancer

Volumn 16, Issue 1, 2016, Pages

  Sun, Xiao Jiang ^a   Deng, Qing Hua ^a   Yu, Xin Min ^a   Ji, Yong Lin ^a   Zheng, Yuan Da ^a   Jiang, Hao ^b   Xu, Ya Ping ^a   Ma, Sheng Lin ^a  

^a ZHEJIANG CANCER HOSPITAL   (China)

^b ZHEJIANG HOSPITAL   (China)

Author keywords

Clinical trial; Concurrent chemoradiotherapy; Endostatin; NSCLC

Indexed keywords

CARBOPLATIN; ENDOSTATIN; PACLITAXEL;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; MALE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; REMISSION;

ADULT; AGED; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; ENDOSTATINS; FEMALE; HUMANS; MALE; MIDDLE AGED; PACLITAXEL; REMISSION INDUCTION;

EID: 84963522515     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-016-2234-0     Document Type: Article

References (18)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90.
2. Furuse K, Fukuoka M, Kawahara M, Nishikawa H, Takada Y, Kudoh S, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol. 1999;17(9):2692-9.
3. Curran Jr WJ, Paulus R, Langer CJ, Komaki R, Lee JS, Hauser S, et al. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst. 2011;103(19):1452-60.
4. Folkman J, Klagsbrun M. Angiogenic factors. Science. 1987;235(4787):442-7.
5. Folkman J. Endogenous inhibitors of angiogenesis. Harvey Lect. 1996;92:65-82.
6. Ge W, Cao DD, Wang HM, Jie FF, Zheng YF, Chen Y. Endostar combined with chemotherapy versus chemotherapy alone for advanced NSCLCs: a meta-analysis. Asian Pac J Cancer Prev. 2011;12(10):2705-11.
7. Han B, Xiu Q, Wang H, Shen J, Gu A, Luo Y, et al. A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of paclitaxel-carboplatin alone or with endostar for advanced non-small cell lung cancer. J Thorac Oncol. 2011;6(6):1104-9.
8. Zhao X, Mei K, Cai X, Chen J, Yu J, Zhou C, et al. A randomized phase II study of recombinant human endostatin plus gemcitabine/cisplatin compared with gemcitabine/cisplatin alone as first-line therapy in advanced non-small-cell lung cancer. Invest New Drugs. 2012;30(3):1144-9.
9. Itasaka S, Komaki R, Herbst RS, Shibuya K, Shintani T, Hunter NR, et al. Endostatin improves radioresponse and blocks tumor revascularization after radiation therapy for A431 xenografts in mice. Int J Radiat Oncol Biol Phys. 2007;67(3):870-8.
10. Luo X, Slater JM, Gridley DS. Enhancement of radiation effects by pXLG-mEndo in a lung carcinoma model. Int J Radiat Oncol Biol Phys. 2005;63(2):553-64.
11. Englert S, Kieser M. Optimal adaptive two-stage designs for phase II cancer clinical trials. Biom J. 2013;55(6):955-68.
12. Wang L, Wu S, Ou G, Bi N, Li W, Ren H, et al. Randomized phase II study of concurrent cisplatin/etoposide or paclitaxel/carboplatin and thoracic radiotherapy in patients with stage III non-small cell lung cancer. Lung Cancer. 2012;77(1):89-96.
13. Boehle AS, Kurdow R, Schulze M, Kliche U, Sipos B, Soondrum K, et al. Human endostatin inhibits growth of human non-small-cell lung cancer in a murine xenotransplant model. Int J Cancer. 2001;94(3):420-8.
14. Iizasa T, Chang H, Suzuki M, Otsuji M, Yokoi S, Chiyo M, et al. Overexpression of collagen XVIII is associated with poor outcome and elevated levels of circulating serum endostatin in non-small cell lung cancer. Clin Cancer Res. 2004;10(16):5361-6.
15. Ni Q, Ji H, Zhao Z, Fan X, Xu C. Endostar, a modified endostatin inhibits non small cell lung cancer cell in vitro invasion through osteopontin-related mechanism. Eur J Pharmacol. 2009;614(1-3):1-6.
16. Patton JF, Spigel DR, Greco FA, Liggett WH, Zubkus LD, Baskette M, et al. Irinotecan (I), carboplatin (C), and radiotherapy (RT) followed by maintenance bevacizumab (B) in the treatment (tx) of limited-stage small cell lung cancer (LS-SCLC): Update of a phase II trial of the Minnie Pearl Cancer Res Network. J Clin Oncol. 2006;24(385a):7085).
17. Spigel DR, Hainsworth JD, Yardley DA, Raefsky E, Patton J, Peacock N, et al. Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(1):43-8.
18. Socinski MA, Morris DE, Halle JS, Moore DT, Hensing TA, Limentani SA, et al. Induction and concurrent chemotherapy with high-dose thoracic conformal radiation therapy in unresectable stage IIIA and IIIB non-small-cell lung cancer: a dose-escalation phase I trial. J Clin Oncol. 2004;22(21):4341-50.